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ARTICLE OPEN
Inﬂuence of lung function on course of disease and response to
antibiotic therapy in adult primary care patients with acute
cough: a post hoc analysis of patients enrolled in a prospective
multicentre study
Nicole van Erp1, Paul Little2, Beth Stuart2, Michael Moore2, Mike Thomas2, Chris C Butler3, Kerenza Hood3, Samuel Coenen4,5,
Herman Goossens4, Margareta Leven4 and Theo JM Verheij1 on behalf of the GRACE consortium
BACKGROUND: In acute cough patients, impaired lung function as present in chronic lung conditions like asthma and chronic
obstructive pulmonary disease (COPD) are often thought to negatively inﬂuence course of disease, but clear evidence is lacking.
AIMS: To investigate the inﬂuence of lung function abnormalities on course of disease and response to antibiotic therapy in
primary care patients with acute cough.
METHODS: A total of 3,104 patients with acute cough (⩽28 days) were included in a prospective observational study with a within-
nested trial, of which 2,427 underwent spirometry 28–35 days after inclusion. Inﬂuence of the lung function abnormalities ﬁxed
obstruction (forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio o0.7) and bronchodilator responsiveness (FEV1
increase of ⩾ 12% or 200ml after 400 μg salbutamol) on symptom severity, duration and worsening were evaluated using uni- and
multivariable regression models. Antibiotic use was deﬁned as the reported use of antibiotics ⩾ 5 days in the ﬁrst week. Interaction
terms were calculated to investigate modifying effects of lung function on antibiotic effect.
RESULTS: The only signiﬁcant association was the effect of severe airway obstruction on symptom severity on days 2–4
(difference = 0.31, 95% conﬁdence interval (CI) = 0.03–0.60, P= 0.03). No evidence of a differential effect of lung function on the
effect of antibiotics was found. Prior use of inhaled steroids was associated with a 30% slower resolution of symptoms rated
‘moderately bad’ or worse (hazard ratio = 0.75, 95% CI = 0.63–0.90, P= 0.00).
CONCLUSIONS: In adult patients with acute cough, lung function abnormalities were neither signiﬁcantly associated with course of
disease nor did they modify the effect of antibiotics.
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INTRODUCTION
Acute cough is one of the most common reasons for people to
consult their general practitioner (GP).1–3 The majority of these
acute cough episodes are caused by mild and self-limiting lower
respiratory tract infections (RTIs) and do not require antibiotic
therapy. However, it is possible that patients with underlying lung
diseases such as asthma or chronic obstructive pulmonary disease
(COPD) suffer from unusually prolonged or severe illness which
would beneﬁt from targeted and adapted therapy.
Approximately 20% of the visits to the GP for lower respiratory
tract symptoms are in patients with abnormal lung function as
seen in asthma or COPD.4 These episodes, referred to as
exacerbations of the underlying chronic lung disorder, contribute
to poor quality of life, mortality and progression of lung disease.5–7
Whether these episodes, often with acute cough as one of the
main symptoms, show a more severe and of prolonged duration
compared with cough episodes in otherwise healthy patients is,
however, unknown. More importantly, antibiotic treatment for
these exacerbations of chronic lung disorders in primary care is
still controversial.8–10
A better understanding of the inﬂuence of impaired lung
function on course of disease and response to antibiotics could
lead to improved patient education and targeted antibiotic
prescribing. The aim of the present study was therefore to further
evaluate inﬂuence of lung function on course of disease and
response to antibiotic therapy in patients with acute cough in
primary care.
MATERIALS AND METHODS
Study design and patients
Data from the GRACE-09 and GRACE-10 studies (Genomics to combat
Resistance against Antibiotics in Community-acquired lower RTIs in Europe;
www.grace-lrti.org) were used. In this prospective observational study
(GRACE-09) with a within nested randomised placebo-controlled double-
blind trial (GRACE-10), data were collected in 16 primary care research
networks in 12 European countries. Participating GPs recruited consecutive
patients from October 2007 until April 2010.
Eligible patients were at least 18 years old, consulting their GP with a
new episode of acute or worsened cough (duration ⩽ 28 days) as the main
symptom. Previous diagnoses of asthma, COPD and other comorbid
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disorders were not exclusion criteria, and thus acute infective exacerba-
tions were included. Criteria for exclusion and further details about
GRACE-09 and GRACE-10 are described in detail elsewhere.11,12 The study
was approved by ethics committees in all participating countries and all
subjects provided written informed consent.
Measurements
Symptoms. At baseline clinicians recorded signs and symptoms as well as
comorbidities and use of medication. After this ﬁrst visit, patients received
a diary on symptoms and daily activities to complete during their illness (to
a maximum of 28 days). Each symptom was rated on a scale from 0 to 6
(0 = no problem, 1 = very little problem, 2 = slight problem, 3 =moderately
bad, 4 = bad, 5 = very bad, 6 = as bad as it could be). This diary was
previously validated and had been proven sensitive to change and
internally reliable.13 If the diary was not returned after 4 weeks, brief
information about symptom duration and severity with either a short
questionnaire or a standardised telephone call.
Spirometry. Between 28 and 35 days after inclusion spirometry was
performed according to a strict protocol. The aim of this timing was to
obtain results during a stable phase.14,15 Staff in the participating centers
underwent standardised training in spirometry. Measurements included
the forced vital capacity (FVC), the forced expiratory volume in 1 s (FEV1)
and the peak expiratory ﬂow before and at least 15 min after
bronchodilation with 400 μg of salbutamol. The best of a minimum of
three acceptable retained ﬂow volume curves was used to determine the
post-bronchodilator FEV1/FVC ratio.
14
Deﬁnition of lung function abnormalities. ‘Fixed airway obstruction’ was
deﬁned as a post-bronchodilator FEV1/FVC ratio o0.7, according to the
Global Initiative for Chronic Obstructive Lung Disease criteria.14 Three
obstruction severity groups based on FEV1 percentage of predicted were
deﬁned: mild obstruction (FEV1⩾ 80% predicted), moderate obstruction
(50⩽ FEV1o80% predicted) and severe obstruction (FEV1o50% pre-
dicted). ‘Bronchodilator responsiveness’ was diagnosed if FEV1 increase of
⩾ 12% or more than 200ml occurred after bronchodilation. In addition, we
selected those patients with bronchodilator responsiveness who also
reported recurrent (more than one episode) wheezing, cough or chest
tightness in the past year. These patients are referred to as patients with
‘symptomatic bronchoconstriction’. Patients with both ﬁxed airway
obstruction and bronchodilator responsiveness were classiﬁed as having
ﬁxed obstruction and were not included in the analyses concerning
bronchodilator responsiveness. This was decided as it is recognised that
patients with COPD frequently but inconsistently exhibit modest
bronchodilator responsiveness and that this does not inﬂuence response
to inhaled therapy.16
Antibiotic use. Antibiotic use was deﬁned as the reported intake of
antibiotics for 5 days or more in the ﬁrst week after consultation, as this is
the duration of use by which bacteria should have been eradicated, and
the use of antibiotics after the ﬁrst week would be unlikely to inﬂuence the
main outcomes under investigation. For those in the nested trial, antibiotic
therapy consisted of 1 g amoxicillin three times daily. Subjects in the
observational cohort reported in diaries whether they were prescribed
antibiotics, the type and dose, and whether they took their medication on
each day.
Outcome measures. Three key outcomes were speciﬁed as primary
outcomes for the trial to capture important symptomatic outcomes for
patients:17 symptom severity on days 2–4 after the index consultation,
duration of symptoms rated by patients as ‘moderately bad’ or worse, and
the occurrence of new or worsening symptoms, deﬁned as a return to the
physician with worsening symptoms, new symptoms or signs, or illness
that made hospital admission necessary within 4 weeks after the ﬁrst
consultation. In addition, effects on duration of symptoms until complete
resolution were assessed.
Data analysis. Data were analysed using linear regression models. Simple
linear regression was used for symptom severity, Cox regression allowing
for censoring for the duration of symptoms and logistic regression for the
occurrence of new or worsened symptoms. In the multivariable analyses
we controlled for the potentially confounding factors age, gender, baseline
severity, duration of prior cough, chronic use of inhaled steroids, current
smoking, the coexistence of heart disease, antibiotic use and use of inhaled
bronchodilators and inhaled corticosteroids (ICSs) during this cough
episode. As ﬁxed obstruction and bronchodilator responsiveness of up to
200ml in FEV1 are frequently seen together, the multivariable analyses
concerning ‘ﬁxed obstruction’ controlled for ‘bronchodilator
responsiveness’.
The effects of antibiotics were analysed both in the observational study
and in the within-nested randomised clinical trial. To investigate the effect
of antibiotics in patients with abnormal lung function test results,
interaction terms between antibiotic use and ﬁxed obstruction and
antibiotic use and bronchodilator responsiveness were calculated and
used as an independent factor in the statistical models. To forestall
confounding by indication for patients in the observational cohort,
propensity scores were calculated and included in the multivariate models
to control for. All data analyses were performed using SPSS version 20.0 for
Windows (IBM Corporation, Armonk, NJ, USA). The signiﬁcance level was
set at 5%.
RESULTS
Patient characteristics
A total of 3,104 eligible patients with acute cough were recruited,
of which 2,581 (83%) underwent spirometry. Patients with
incomplete spirometry results (n= 154) were excluded, resulting
in 2,427 subjects for analysis (Figure 1). The mean age of the total
study population (n= 2,427) was 50.8 (s.d. = 16.5) and 59.5%
(n= 1,454) of the patients were female. Table 1 shows the baseline
characteristics of all patients, sorted by lung function abnormality
after 4 weeks and by antibiotic use.
Lung function abnormalities
Patients with ﬁxed lung function obstruction of any severity
category were older, more often male, more often current smokers
and more often chronic inhaled medication users. Of the patients
that met the criteria for ﬁxed obstruction (n= 323), only 12.4%
(mild obstruction) to 37.2% (severe obstruction) were previously
diagnosed with COPD, suggesting that signiﬁcant numbers of
patients presenting to GPs with an acute cough may have
previously undiagnosed COPD. On the other hand, of the patients
Figure 1. Flowchart patient selection. Numbers of patients enrolled
in the GRACE-09 and GRACE-10 studies and those selected for our
analyses.
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with previously diagnosed COPD (n= 157), only 79 (50.3%)
showed a ﬁxed obstruction during the present spirometry,
suggesting overdiagnosis.
Patients with bronchodilator responsiveness were more often
male and current smokers, but otherwise did not differ
signiﬁcantly from the patients without this abnormality. Patients
with lung function abnormalities, both ﬁxed obstruction and
responsiveness, did not present with more severe or longer-
existing symptoms at baseline than people without (Table 1).
Antibiotic use
Of all 2,427 patients, 1,626 were included in the randomised
controlled trial with 821 patients in the amoxicillin group and 805
patients in the placebo group. All the other patients (n= 801) were
part of the observational study, of which 394 patients were
prescribed antibiotics by their GP. When analysed together and
regarding actual use of antibiotics (per protocol analysis), 896
patients (36.9%) used antibiotics for 5 days or more in the ﬁrst
week compared with 1,327 (54.7%) patients who did not. In 204
patients (8.4%) actual antibiotic use was not reported.
Course of disease
Only in the outcome measure mean symptom severity on days
2–4, there was a signiﬁcant difference between patients with and
without severe airway obstruction in the multivariable analysis
(difference = 0.31, 95% conﬁdence interval (CI) = 0.03–0.60,
P= 0.03). A similar effect was seen for ‘symptomatic bronchocon-
striction’ (difference = 0.12, 95% CI = 0.01–0.23, P= 0.03) (Table 2).
For all other outcome parameters, no signiﬁcant effects of any of
Table 1. Baseline characteristics of all patients with valid spirometry results by antibiotic use and lung function abnormalities
Characteristics All patients Fixed airway obstructiona Responsivenessb Symptomatic
bronchoconstrictionc
Antibiotic used
No Mild Moderate Severe Yes No
Number of patients 2,427 (100.0%) 2,104 (86.7) 121 (5.0) 159 (6.6) 43 (1.8) 470 (19.4) 274 (11.3) 896 (36.9) 1,327 (54.7)
Age, mean (s.d.) 50.8 (16.5) 49.4 (16.3) 57.3 (15.9) 62.6 (13.6) 58.7 (17.3) 45.7 (16.5) 44.5 (15.7) 50.5 (16.1) 51.7 (16.2)
Women, n (%) 1,454 (59.5) 1281 (60.9) 65 (53.7) 82 (51.6) 17 (39.5) 250 (53.2) 158 (57.7) 537 (59.9) 793 (59.8)
Current smoking, n
(%)
651 (26.8) 538 (25.6) 36 (29.8) 61 (38.4) 16 (37.2) 138 (29.4) 91 (33.2) 255 (28.5) 338 (25.5)
Pack years of
smoking, mean
(s.d.)
17.1 (18.0) 14.9 (15.5) 24.1 (27.0) 28.8 (22.4) 33.9 (25.6) 14.1 (15.7) 13.8 (14.3) 17.3 (17.5) 17.5 (18.7)
Coexisting conditions, n (%)
COPD 157 (6.5) 78 (3.7) 15 (12.4) 48 (30.2) 16 (37.2) 15 (3.2) 13 (4.7) 69 (7.7) 80 (6.0)
Asthma 253 (10.4) 204 (9.7) 14 (11.6) 28 (17.6) 7 (16.3) 63 (13.4) 49 (17.9) 93 (10.4) 141 (10.6)
Heart (HF, IHD,
other)
227 (9.4) 179 (8.5) 10 (8.3) 30 (18.9) 8 (18.6) 32 (6.8) 18 (6.6) 88 (9.8) 119 (9.0)
Diabetes mellitus 164 (6.8) 133 (6.3) 6 (5.0) 20 (12.6) 5 (11.6) 36 (7.7) 19 (6.9) 61 (6.8) 92 (6.9)
Use of inhaled lung medication, n (%)
Bronchodilators 290 (11.9) 199 (9.5) 21 (17.4) 55 (34.6) 15 (34.9) 52 (11.1) 46 (16.8) 109 (12.2) 159 (12.0)
Steroids 231 (9.5) 163 (7.7) 17 (14.0) 39 (24.5) 12 (27.9) 44 (9.4) 37 (13.5) 89 (9.9) 127 (9.6)
Symptoms at consultation, mean (s.d.)
Mean baseline
severity of
symptoms, 1–4
2.09 (0.5) 2.09 (0.5) 2.05 (0.6) 2.07 (0.5) 1.95 (0.4) 2.13 (0.5) 2.17 (0.5) 2.09 (0.5) 2.08 (0.5)
Duration of prior
illness, days
9.44 (7.5) 9.45 (7.4) 9.19 (6.6) 9.61 (9.8) 9.0 (6.9) 9.13 (7.0) 9.31 (7.0) 9.24 (7.4) 9.64 (7.5)
Duration of prior
cough, days
8.56 (6.8) 8.58 (6.9) 8.66 (6.4) 8.13 (6.1) 8.51 (6.9) 8.51 (6.7) 8.79 (7.0) 8.44 (7.0) 8.72 (6.7)
Antibiotics, n (%)
Assigned (trial) 821 (33.8) 720 (34.2) 41 (33.9) 49 (30.8) 11 (25.6) 161 (34.3) 95 (34.7) 699 (78.0) 58 (4.4)
Prescribed
(observational)
394 (16.2) 326 (15.5) 21 (17.4) 35 (22.0) 12 (27.9) 66 (14.0) 41 (15.0) 175 (19.5) 215 (16.2)
Spirometry (± day 28), mean (s.d.)
FEV1, litres, post
bronchodilation
2.97 (2.35) 3.12 (2.48) 2.54 (0.73) 1.79 (0.46) 1.25 (0.43) 3.53 (3.98) 3.62 (5.15) 3.03 (2.96) 2.88 (0.93)
FVC, litres, post
bronchodilation
3.64 (1.07) 3.68 (1.06) 3.98 (1.06) 3.00 (0.86) 2.81 (1.10) 4.05 (1.16) 4.04 (1.21) 3.67 (1.03) 3.61 (1.07)
FEV1/FVC, post
bronchodilation
0.82 (0.72) 0.85 (0.77) 0.64 (0.09) 0.60 (0.07) 0.47 (0.12) 0.88 (1.14) 0.91 (1.49) 0.83 (0.84) 0.80 (0.10)
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; HF, heart failure; IHD, ischemic
heart disease.
aPatients with both bronchodilator responsiveness and ﬁxed airway obstruction are included here.
bBronchodilator responsiveness only, no ﬁxed airway obstruction.
cPatients with bronchodilator responsiveness only and reported complaints of recurrent cough, wheezing or chest tightness during the last year.
dDeﬁned as the use of antibiotics for 5 days or more in the ﬁrst week.
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the lung function abnormality groups were seen after controlling
for confounders (Tables 3, 4 and 5).
We found that 231 patients (9.5%) were receiving maintenance
treatment with ICSs at the time of presentation. Long-term use of
inhaled steroids was associated with a 30% slower resolution of
symptoms rated ‘moderately bad’ or worse (12.2 days versus
9.2 days in patients without inhaled steroids, hazard ratio
(HR) = 0.75, 95% CI = 0.63–0.90, Po0.001) and a 15% slower
resolution of symptoms until complete resolution (18.3 days
versus 15.9 days, HR= 0.65, 95% CI = 0.52–0.83, Po0.001) in
multivariate regression models. Similarly, a prior physician
diagnosis of COPD (n= 157, 6.5%) was associated with a slower
resolution of symptoms rated ‘moderately bad’ or worse (12.4 days
in patients with this diagnosis versus 9.3 days in patients without,
HR= 0.77, 95% CI = 0.62–0.95, P= 0.02).
Effect of antibiotics
Antibiotic use was included in regression models of all four main
outcomes, and was not an independent predictive factor for
severity of symptoms on days 2–4, duration of symptoms or
occurrence of new or worsened symptoms. In addition, there
was no evidence for an interaction between ﬁxed airway
obstruction and the use of antibiotics on mean severity of
symptoms (B interaction term coefﬁcient = 0.05, 95% CI =− 0.13 to
0.24, P= 0.58), duration of symptoms rated ‘moderately bad’ or
worse (HR = 0.87, 95% CI = 0.71–1.05, P= 0.15), duration of
symptoms until resolution (HR = 0.84, 95% CI = 0.66–1.07,
P= 0.15) or the occurrence of new or worsened symptoms (odds
ratio = 1.26, (0.81–1.95, P= 0.31). No interaction between ‘bronch-
odilator responsiveness’ and antibiotic use was seen on these four
outcomes. The results after controlling for propensity score for the
observational study participants conﬁrmed that the interaction
term was not signiﬁcant in any model (see Supplementary
Appendix Tables 1–4). Therefore no further subgroup analysis
was performed. No different results were found in trial patients
only (data not shown).
DISCUSSION
Main ﬁndings
In adult patients who consulted for acute cough in primary care
and who underwent pre- and post-bronchodilator spirometry
4 weeks later, lung function abnormalities deﬁned as ‘ﬁxed airway
obstruction’, ‘bronchodilator responsiveness’ and ‘symptomatic
bronchoconstriction’ did not inﬂuence course of disease in a
clinically meaningful way. Neither ﬁxed airway obstruction nor
bronchodilator responsiveness inﬂuenced the effect of antibiotics.
The use of ICSs was independently associated with prolonged
illness, as was a prior diagnosis of COPD.
Table 2. Inﬂuence of lung function abnormalities on mean severity of symptoms on days 2–4
Univariable coefﬁcient B (95% CI) P value Multivariable coefﬁcient B (95% CI)a P value
Fixed airway obstruction 0.04 (−0.09 to 0.15) 0.57 0.04 (−0.07 to 0.15) 0.44
Obstruction severity
No obstruction 1 (reference) 1 (reference)
Mild − 0.04 (−0.23 to 0.14) 0.65 0.00 (−0.16 to 0.17) 0.98
Moderate 0.05 (−0.12 to 0.22) 0.56 0.01 (−0.14 to 0.16) 0.91
Severe 0.20 (−0.11 to 0.51) 0.20 0.31 (0.03 to 0.60) 0.03
Bronchodilator responsiveness 0.06 (−0.04 to 0.16) 0.26 0.00 (−0.09 to 0.09) 0.99
‘Symptomatic bronchoconstriction’b 0.25 (0.12 to 0.38) o0.001 0.12 (0.01 to 0.23) 0.03
Abbreviation: CI, conﬁdence interval.
aControlled for factors: age (increase in years), gender, baseline severity of symptoms, duration of prior cough (days), chronic use of corticosteroids, current
smoking, underlying heart disease, (bronchodilator responsiveness), use of antibiotics for 5 days or more in the ﬁrst week, use of inhalation steroids during
cough episode, use of bronchodilators during cough episode.
bPatients with bronchodilator responsiveness and reported complaints of recurrent cough, wheezing or chest tightness.
Table 3. Inﬂuence of lung function abnormalities on duration of symptoms rated ‘moderately bad’ or worse
Univariable hazard ratio (95% CI) P value Multivariable hazard ratio (95% CI)a P value
Fixed airway obstruction 0.89 (0.78–1.01) 0.08 0.97 (0.84–1.11) 0.63
Obstruction severity
No obstruction 1 (reference) 1 (reference)
Mild 0.95 (0.78–1.16) 0.62 0.94 (0.76–1.16) 0.57
Moderate 0.89 (0.75–1.07) 0.22 1.05 (0.86–1.27) 0.64
Severe 0.72 (0.51–1.02) 0.07 0.77 (0.52–1.14) 0.19
Bronchodilator responsiveness 1.04 (0.93–1.16) 0.51 1.02 (0.90–1.14) 0.80
‘Symptomatic bronchoconstriction’b 0.93 (0.81–1.06) 0.27 0.94 (0.82–1.09) 0.40
Abbreviation: CI, conﬁdence interval.
aControlled for factors: age (increase in years), gender, baseline severity of symptoms, duration of prior cough (days), chronic use of corticosteroids, current
smoking, underlying heart disease, (bronchodilator responsiveness), use of antibiotics for 5 days or more in the ﬁrst week, use of inhalation steroids during
cough episode, use of bronchodilators during cough episode.
bPatients with bronchodilator responsiveness and reported complaints of recurrent cough, wheezing or chest tightness.
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Interpretation of ﬁndings in relation to previously published work
The general presumption, although lacking a ﬁrm evidence-base,
is that patients with abnormal lung function and with pre-existing
airways disease will suffer from more severe symptoms and a
longer duration of illness. However, as asthma and COPD patients
are usually regarded as separate groups in medical research, we
are aware of no studies directly comparing healthy individuals
with patients with asthma or COPD.
Hopstaken et al.10 reported physician-diagnosed asthma to be
an independent predictor of delayed symptom resolution in RTI.
This ﬁnding was not conﬁrmed by our study. Neither measured
bronchodilator responsiveness, with or without reported com-
plaints of recurrent cough, wheezing or chest tightness, nor a prior
diagnosis of asthma, were found to be independent predictors of
a prolonged disease in our study. Comparison between our study
and Hopstaken’s is, however, hampered by differences in study
size, deﬁnitions and use of measurements. In our larger study,
neither a prior diagnosis of asthma nor recurrent episodes of
respiratory symptoms combined with bronchodilator responsive-
ness were associated with length or severity of illness nor with a
response to antibiotics.
While lung function abnormalities as measured by spirometry
were no independent predictors of course of disease, both long-
term use of ICSs and a prior diagnosis of COPD were independent
predictors of duration of symptoms rated ‘moderately bad’ or
worse. These two characteristics were probably markers for a more
severe underlying disorder or risk for a more serious course of
disease. In the case of a diagnosis of COPD, this is somewhat
remarkable since spirometry results were normal in half of these
patients. A possible explanation could be that the physician
diagnosis of ‘COPD’ included a subgroup that did not meet the
physiological criteria required for COPD diagnosis but previously
had suffered from frequent and prolonged episodes for other,
perhaps, immunological reasons. Further research to understand
this ﬁnding is needed.
In the existing literature ICS use is associated with an increased
risk of pneumonia in patients with COPD,18 and new evidence
shows similar results for asthma patients.19 However, the effects
on RTI severity and duration have not been studied in a large
representative group of patients treated in the community such as
those in our study. There is biological plausibility in the contention
that long-term inhaled steroid use could have effects on RTI, and
our data suggest that it might be an independent predictor of a
prolonged course of disease, regardless of lung function. This
ﬁnding also warrants further research.
Regarding antibiotic use in patients with abnormal lung
function, our ﬁndings are consistent with other studies. A recent
Cochrane review shows effects of antibiotics for exacerbations of
COPD in patients admitted to an ICU, but in patients with mild and
moderate exacerbations, more likely to be seen by the GP, there is
limited evidence of the effectiveness of currently available
antibiotics.9 In asthma, two studies including 97 participants
Table 4. Inﬂuence of lung function abnormalities on duration of symptoms until complete resolution
Univariable hazard ratio (95% CI) P value Multivariable hazard ratio (95% CI)a P value
Fixed airway obstruction 0.84 (0.72–0.98) 0.03 0.97 (0.81–1.15) 0.70
Obstruction severity
No obstruction 1 (reference) 1 (reference)
Mild 0.99 (0.77–1.25) 0.93 1.02 (0.79–1.31) 0.88
Moderate 0.73 (0.59–0.91) 0.01 0.93 (0.73–1.18) 0.54
Severe 0.87 (0.59–1.29) 0.49 0.94 (0.58–1.53) 0.81
Bronchodilator responsiveness 1.14 (1.01–1.30) 0.04 1.09 (0.95–1.25) 0.25
‘Symptomatic bronchoconstriction’b 0.93 (0.78–1.09) 0.34 0.91 (0.77–1.09) 0.31
Abbreviation: CI, conﬁdence interval.
aControlled for factors: age (increase in years), gender, baseline severity of symptoms, duration of prior cough (days), chronic use of corticosteroids, current
smoking, underlying heart disease, (bronchodilator responsiveness), use of antibiotics for 5 days or more in the ﬁrst week, use of inhalation steroids during
cough episode, use of bronchodilators during cough episode.
bPatients with bronchodilator responsiveness and reported complaints of recurrent cough, wheezing or chest tightness.
Table 5. Inﬂuence of lung function abnormalities on occurrence of new/worsened symptoms
Univariable odds ratio (95% CI) P value Multivariable odds ratio (95% CI)a P value
Fixed airway obstruction 1.00 (0.74–1.36) 1.00 1.01 (0.72–1.41) 0.98
Obstruction severity
No obstruction 1 (reference) 1 (reference)
Mild 1.16 (0.74–1.83) 0.52 1.16 (0.71–1.88) 0.56
Moderate 0.84 (0.54–1.31) 0.45 0.82 (0.51–1.31) 0.40
Severe 1.17 (0.56–2.46) 0.68 1.41 (0.62–3.22) 0.41
Bronchodilator responsiveness 1.01 (0.78–1.31) 0.94 0.96 (0.72–1.29) 0.79
‘Symptomatic bronchoconstriction’b 0.88 (0.63–1.24) 0.47 0.87 (0.61–1.24) 0.43
Abbreviation: CI, conﬁdence interval.
aControlled for factors: age (increase in years), gender, baseline severity of symptoms, duration of prior cough (days), chronic use of corticosteroids, current
smoking, underlying heart disease, (bronchodilator responsiveness), use of antibiotics for 5 days or more in the ﬁrst week, use of inhalation steroids during
cough episode, use of bronchodilators during cough episode.
bPatients with bronchodilator responsiveness and reported complaints of recurrent cough, wheezing or chest tightness.
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included in a Cochrane review show insufﬁcient evidence to
support the use of antibiotics.20
Strengths and limitations of this study
A major strength of this study is the large sample size. In addition,
as this study recruited patients consulting their GP with acute
cough in 12 European countries using broad inclusion criteria,
these ﬁndings are based on a clinically relevant population and
therefore are highly generalisable.
Lung function was assessed using the spirometers already
available in the participating primary care practices. Because of
this, measurements were obtained by a range of different
spirometer models. However, spirometry was performed accord-
ing to a strict protocol at all study sites and participating staff were
adequately trained to perform spirometry and analyse curves. It
has been shown that spirometry tests in primary care conducted
by appropriately skilled and trained staff are comparable in quality
to pulmonary function laboratory measurements.21
Lung function was measured 4 weeks after the index
consultation to avoid temporary airway obstruction or respon-
siveness caused by the RTI. However, some of the patients may
still have had a prolonged temporary airway hyperreactivity due
to their infection.15 It is, however, not likely that this will have
biased results signiﬁcantly in patients without asthma or COPD. In
addition, spirometry results of patients with asthma vary over time
and may be completely normal at any given moment and in the
absence of exposure to triggers.22 Consequently, it is possible that
a proportion of the patients with normal spirometry may have had
asthma, which could have been detected by more sophisticated
tests such as measures of bronchial hyperreactivity or airways
inﬂammation.
Patients with a pre-existing diagnosis of asthma or COPD were
included in this analysis. How these diagnostic labels were given
was not recorded and thus should be assumed to be varying as is
the case in routine daily primary care. When interpreting the
relations between previous diagnosis of asthma and COPD, this
should be taken into account. The same applies for the treatments
at baseline that patients used. These baseline characteristics all
reﬂect daily routine in primary care and were not given according
to a study protocol or standardised guidelines.
For this study it was decided to combine data from a nested
trial and an observational part of a study cohort. These two groups
of patients are not completely comparable as some patients were
deliberately withheld from randomisation for several possible
reasons, raising the possibility of bias. In addition, the antibiotic
used in the trial was amoxicillin 1 g three times daily while in the
observational study the type and dose of antibiotics varied.
However, this potential limitation was controlled for by adjusting
for possible differences in baseline characteristics in our regression
models. In addition, we calculated propensity scores for all
observational patients to control for confounding by indication.
The same results were found with these scores included in the
multivariable statistical models. A subanalysis of trial patients only
showed similar results.
Conclusion and implications for future research, policy and
practice
Overall, this study found little inﬂuence of lung function on course
of disease in adult patients presenting in primary care with acute
cough. In addition, no effect of antibiotics was apparent in
patients with ﬁxed airﬂow obstruction or bronchodilator reversi-
bility. This suggests that undetected lung function abnormalities
pose no relevant short-term clinical problems for GPs while
diagnosing and treating patients with acute cough. The course of
disease in these patients is usually mild, self-limiting and not
improved by antibiotics. No extensive diagnostic procedures are
warranted immediately, and monitoring of recurrent and
prolonged signs and symptoms within a somewhat larger
timeframe still seems a good approach.
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